Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
A new address purchased $7,500 worth of Biden as the probability of his son becoming the 2028 Democratic presidential candidate surged threefold.

A new address purchased $7,500 worth of Biden as the probability of his son becoming the 2028 Democratic presidential candidate surged threefold.

Odaily星球日报Odaily星球日报2026/06/05 03:00
Show original

Odaily Seer monitoring shows that a newly created address on Polymarket bought $7,500 worth of Hunter Biden to become the 2028 Democratic presidential candidate, with an average purchase price of 0.7¢.

Possibly influenced by this, several wallets followed suit and bought in, pushing the probability from 0.7% up to the current 2.9%.

Reportedly, Hunter Biden is the second son of Joe Biden, the 46th President of the United States, and is his only surviving son. Related controversies have run throughout President Biden's term, becoming a core weapon for the Republican Party to attack the Biden administration for "corruption" and "nepotism".

Odaily Seer continues to monitor prediction markets, seeing changes before pricing occurs.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage